Related Experiment Video

Updated: Jun 4, 2026

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides

Philippe Denoël1, Fabrice Godfroid, Philippe Hermand

  • 1Research & Development, GlaxoSmithKline Biologicals, Rue de l'Institut 89, B-1330 Rixensart, Belgium.

Vaccine
|February 15, 2011
PubMed

Insights

A new study shows combining PhtD vaccination with antibodies against pneumococcal serotypes 1 and 3 enhances protection against pneumonia. This approach offers a promising strategy for preventing severe childhood pneumonia cases.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Increasing prevalence of complicated childhood pneumonia linked to specific pneumococcal serotypes (1 and 3).
  • Pneumococcal serotypes 1 and 3 are significant contributors to pneumonia burden.
  • Need for effective preventative strategies against pneumococcal infections.

Purpose of the Study:

  • To evaluate the protective efficacy of a combined immunization strategy against pneumococcal pneumonia.
  • To assess the additive protective effect of PhtD vaccination and specific anti-polysaccharide antibodies.

Main Methods:

  • Utilized a lethal intranasal challenge mouse model for pneumococcal pneumonia.
  • Administered vaccination with PhtD (a vaccine candidate protein antigen).
  • Administered injected antibodies targeting pneumococcal serotypes 1 and 3.

Main Results:

  • Demonstrated a significant additive protective effect when combining PhtD vaccination with anti-serotype 1 and 3 antibodies.
  • The combined approach showed enhanced protection compared to individual components.
  • Successful mitigation of lethal pneumococcal challenge in the mouse model.

Conclusions:

  • The combination of PhtD vaccination and specific anti-polysaccharide antibodies provides enhanced protection against pneumococcal pneumonia.
  • This dual strategy is a promising candidate for preventing severe pneumonia caused by pneumococcal serotypes 1 and 3.
  • Further research into this combined approach could lead to improved vaccines for childhood pneumonia.

More Related Videos

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...